Tumor suppressor function of the calcium/phospholipid-binding Annexin-A7 (ANXA7) has been shown in Anxa7-deficient mice and validated in human cancers, particularly for prostate cancer [23, 33]. This evidence concerns the gene ANXA7 and prostate carcinoma.